CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells

Abstract Background Various nanocarriers have been used to deliver subunit vaccines specifically to dendritic cells (DCs) for the improvement of immunogenicity. However, due to their insufficient DC priming ability, these vaccines could not elicit effective innate immunity. We have recently develope...

Full description

Bibliographic Details
Main Authors: Hidenori Matsuo, Masaharu Somiya, Masumi Iijima, Takeshi Arakawa, Shun’ichi Kuroda
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Nanobiotechnology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12951-018-0386-6
id doaj-81e749a58d104ce4aefe4a8ccc2d29dd
record_format Article
spelling doaj-81e749a58d104ce4aefe4a8ccc2d29dd2020-11-25T02:11:16ZengBMCJournal of Nanobiotechnology1477-31552018-08-0116111210.1186/s12951-018-0386-6CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cellsHidenori Matsuo0Masaharu Somiya1Masumi Iijima2Takeshi Arakawa3Shun’ichi Kuroda4Graduate School of Bioagricultural Sciences, Nagoya UniversityDepartment of Biomolecular Science and Reaction, The Institute of Scientific and Industrial Research, Osaka UniversityGraduate School of Bioagricultural Sciences, Nagoya UniversityCOMB, Tropical Biosphere Research Center, University of the RyukyusGraduate School of Bioagricultural Sciences, Nagoya UniversityAbstract Background Various nanocarriers have been used to deliver subunit vaccines specifically to dendritic cells (DCs) for the improvement of immunogenicity. However, due to their insufficient DC priming ability, these vaccines could not elicit effective innate immunity. We have recently developed a DC-targeting bio-nanocapsule (BNC) by displaying anti-CD11c IgGs via protein A-derived IgG Fc-binding Z domain on the hepatitis B virus envelope L protein particles (α-DC-ZZ-BNC). Results After the chemical modification with antigens (Ags), the α-DC-ZZ-BNC-Ag complex could deliver Ags to DCs efficiently, leading to effective DC maturation and efficient endosomal escape of Ags, followed by Ag-specific T cell responses and IgG productions. Moreover, the α-DC-ZZ-BNC modified with Japanese encephalitis virus (JEV) envelope-derived D3 Ags could confer protection against 50-fold lethal dose of JEV injection on mice. Conclusion The α-DC-ZZ-BNC-Ag platform was shown to induce humoral and cellular immunities effectively without any adjuvant.http://link.springer.com/article/10.1186/s12951-018-0386-6Bio-nanocapsuleHepatitis B virusVaccineDendritic cellIn vivo targetingProtective immunity
collection DOAJ
language English
format Article
sources DOAJ
author Hidenori Matsuo
Masaharu Somiya
Masumi Iijima
Takeshi Arakawa
Shun’ichi Kuroda
spellingShingle Hidenori Matsuo
Masaharu Somiya
Masumi Iijima
Takeshi Arakawa
Shun’ichi Kuroda
CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
Journal of Nanobiotechnology
Bio-nanocapsule
Hepatitis B virus
Vaccine
Dendritic cell
In vivo targeting
Protective immunity
author_facet Hidenori Matsuo
Masaharu Somiya
Masumi Iijima
Takeshi Arakawa
Shun’ichi Kuroda
author_sort Hidenori Matsuo
title CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
title_short CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
title_full CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
title_fullStr CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
title_full_unstemmed CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
title_sort cd11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells
publisher BMC
series Journal of Nanobiotechnology
issn 1477-3155
publishDate 2018-08-01
description Abstract Background Various nanocarriers have been used to deliver subunit vaccines specifically to dendritic cells (DCs) for the improvement of immunogenicity. However, due to their insufficient DC priming ability, these vaccines could not elicit effective innate immunity. We have recently developed a DC-targeting bio-nanocapsule (BNC) by displaying anti-CD11c IgGs via protein A-derived IgG Fc-binding Z domain on the hepatitis B virus envelope L protein particles (α-DC-ZZ-BNC). Results After the chemical modification with antigens (Ags), the α-DC-ZZ-BNC-Ag complex could deliver Ags to DCs efficiently, leading to effective DC maturation and efficient endosomal escape of Ags, followed by Ag-specific T cell responses and IgG productions. Moreover, the α-DC-ZZ-BNC modified with Japanese encephalitis virus (JEV) envelope-derived D3 Ags could confer protection against 50-fold lethal dose of JEV injection on mice. Conclusion The α-DC-ZZ-BNC-Ag platform was shown to induce humoral and cellular immunities effectively without any adjuvant.
topic Bio-nanocapsule
Hepatitis B virus
Vaccine
Dendritic cell
In vivo targeting
Protective immunity
url http://link.springer.com/article/10.1186/s12951-018-0386-6
work_keys_str_mv AT hidenorimatsuo cd11cspecificbionanocapsuleenhancesvaccineimmunogenicitybytargetingimmunecells
AT masaharusomiya cd11cspecificbionanocapsuleenhancesvaccineimmunogenicitybytargetingimmunecells
AT masumiiijima cd11cspecificbionanocapsuleenhancesvaccineimmunogenicitybytargetingimmunecells
AT takeshiarakawa cd11cspecificbionanocapsuleenhancesvaccineimmunogenicitybytargetingimmunecells
AT shunichikuroda cd11cspecificbionanocapsuleenhancesvaccineimmunogenicitybytargetingimmunecells
_version_ 1724915389123526656